Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

Gower, Arjan; Wang, Yisong; Giaccone, Giuseppe

doi:10.1007/s00109-014-1165-y

Cited by 62 publications

(59 citation statements)

References 116 publications

(151 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,11,14,15 This is largely due to lack of understanding of the biology of these tumors. However, recent genetic studies using comparative genomic hybridization, whole genome expression analysis and next generation sequencing have provided new insights in the biology of this rare cancer.…”

Section: Introductionmentioning

confidence: 99%

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

Alberobello

Wang

Beerkens

et al. 2016

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

Introduction Thymic epithelial tumors (TETs) are rare tumors originating from the epithelia of the thymus, and therapeutic options beyond surgery are limited. Pathogenesis of TETs is poorly understood, and the scarcity of model systems for these rare tumors makes the study of their biology very challenging. Methods A new cell line (MP57) was established from a thymic carcinoma specimen and characterized using standard biomarker analysis, as well as next generation sequencing (NGS), and functional assays. Sanger sequencing was used to confirm the mutations identified by NGS. Results MP57 possesses all the tested thymic epithelial markers and is deemed to be a bona fide thymic carcinoma cell line. NGS analysis of MP57 identified a mutation in PIK3R2, a regulatory subunit of PI3K. Further analysis identified different mutations in multiple PI3K subunits in another cell line and several primary thymic carcinoma samples, including two catalytic subunits (PIK3CA and PIK3CG) and another regulatory subunit (PIK3R4). Inhibiting PI3K with GDC0941 resulted in in vitro antitumor activities in TET cells carrying mutant PI3K subunits. Conclusions Alterations of PI3K, due to mutations in its catalytic or regulatory subunits, is observed in a subgroup of TETs, in particular thymic carcinomas. Targeting PI3K may be an effective strategy to treat these tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

Alberobello

Wang

Beerkens

et al. 2016

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chemo-radiotherapy remains the major treatment method for lung adenocarcinoma but limited success has been achieved in the clinical. With further investigation on the treatment of lung adenocarcinoma, targeted therapy has been intensively researched to improve therapy effect [11].…”

Section: Discussionmentioning

confidence: 99%

The Role of CHMP4C on Proliferation in the Human Lung Cancer A549 Cells

Li¹,

Liu²,

Tian³

et al. 2015

JCT

View full text Add to dashboard Cite

The human lung cancer has high incidence rate and mortality among the carcinoma. The research on enhancing the efficacy of therapy for lung cancer is significant. A resent research found that as a subunit of ESCRT-III, CHMP4C functioned to retard abscission timing to coordinate midbody resolution and prevent accumulation of DNA damage in the abscission checkpoint through phosphorylated by AuroraB. In the current study, we evaluated the possible mechanism of the effects of CHMP4C inhibition on cell cycle and cell survival in A549 cells. We found that CHMP4C knockdown caused lagging S phase in cell cycle through enhancing the phosphorylation of Rb, raising the expression of cyclin B1-cdc2 and suppressing the activation of cyclin A. Meanwhile, CHMP4C deletion depressed cell survival via decreasing cell viability and increasing caspase 3/7 activity. This study may promote new significant reference and advance for the mechanism underlying specific function of CHMP4C as well as further research on enhancing therapy effect on non-small lung cancer.

show abstract

“…cancerhelp.org.uk/type/lung-cancer). Five-year survival remains at approximately 16%, with little improvement observed over the past 30 years (Gower et al, 2014), despite the advances made in surgical and therapeutic interventions. The most important risk factor for lung cancer is smoking, which accounts for up to 85% of all cases (Herbst et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…This, in conjunction with histologic characteristics, guides targeted therapy treatment decisions. Further oncogenic drivers common to NSCLC include BRAF, KRAS, PIK3CA, RET, HER2, and MET (Munoz et al, 2013;Gower et al, 2014), which may exist within a tumor as multiple molecular drivers, ultimately leading to therapeutic resistance.…”

Section: Introductionmentioning

confidence: 99%

Translating Curcumin to the Clinic for Lung Cancer Prevention: Evaluation of the Preclinical Evidence for Its Utility in Primary, Secondary, and Tertiary Prevention Strategies

Howells

Mahale

Sale

et al. 2014

J Pharmacol Exp Ther

View full text Add to dashboard Cite

Lung cancer is responsible for over one million deaths worldwide each year. Smoking cessation for lung cancer prevention remains key, but it is increasingly acknowledged that prevention strategies also need to focus on high-risk groups, including ex-smokers, and patients who have undergone resection of a primary tumor. Models for chemoprevention of lung cancer often present conflicting results, making rational design of lung cancer chemoprevention trials challenging. There has been much focus on use of dietary bioactive compounds in lung cancer prevention strategies, primarily due to their favorable toxicity profile and long history of use within the human populace. One such compound is curcumin, derived from the spice turmeric. This review summarizes and stratifies preclinical evidence for chemopreventive efficacy of curcumin in models of lung cancer, and adjudges the weight of evidence for use of curcumin in lung cancer chemoprevention strategies.

show abstract

Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer

Cited by 62 publications

References 116 publications

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors

The Role of CHMP4C on Proliferation in the Human Lung Cancer A549 Cells

Translating Curcumin to the Clinic for Lung Cancer Prevention: Evaluation of the Preclinical Evidence for Its Utility in Primary, Secondary, and Tertiary Prevention Strategies

Contact Info

Product

Resources

About